Acute Myeloid Leukemia (AML) Clinical Trials

• Participants must have newly diagnosed and previously untreated AML and be candidates for intensive chemotherapy.

• Presence of an NPM1 mutation.

• Eastern Cooperative Oncology Group performance status ≤2 (≤1 if \>65 years old); Karnofsky or Lansky ≥40.

• Have a life expectancy of ≥3 months as judged by the Investigator.

• Negative serum pregnancy test.

• Adequate liver, kidney, and cardiac function.